| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |